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Abstract
Aims To assess the prevalence and management of depressive disorders in people with Type 2 diabetes in different
countries.
Methods People with diabetes aged 18–65 years and treated in outpatient settings were recruited in 14 countries and
underwent a psychiatric interview. Participants completed the Patient Health Questionnaire and the Problem Areas in
Diabetes scale. Demographic and medical record data were collected.
Results A total of 2783 people with Type 2 diabetes (45.3% men, mean duration of diabetes 8.8 years) participated.
Overall, 10.6% were diagnosed with current major depressive disorder and 17.0% reported moderate to severe levels of
depressive symptomatology (Patient Health Questionnaire scores >9). Multivariable analyses showed that, after
controlling for country, current major depressive disorder was significantly associated with gender (women) (P<0.0001),
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a lower level of education (P<0.05), doing less exercise (P<0.01), higher levels of diabetes distress (P<0.0001) and a
previous diagnosis of major depressive disorder (P<0.0001). The proportion of those with either current major
depressive disorder or moderate to severe levels of depressive symptomatology who had a diagnosis or any treatment for
their depression recorded in their medical records was extremely low and non-existent in many countries (0–29.6%).
Conclusions Our international study, the largest of this type ever undertaken, shows that people with diabetes
frequently have depressive disorders and also significant levels of depressive symptoms. Our findings indicate that the
identification and appropriate care for psychological and psychiatric problems is not the norm and suggest a lack of the
comprehensive approach to diabetes management that is needed to improve clinical outcomes.
Diabet. Med. 35, 760–769 (2018)
Introduction
Worldwide, prevalence rates of both diabetes and mental
health problems are increasing rapidly [1–4]. Studies indi-
cate that depression and subthreshold depressive states are
much more common and persistent in people with Type 2
diabetes than in those without [2,5,6]; however, in the past,
most studies have not used both a psychiatric diagnostic
interview and a validated diagnosis of Type 2 diabetes [4,6],
which might have contributed to the differences in preva-
lence data reported. The use of a wide range of checklists
rather than a clinical interview to diagnose depression makes
the findings of these studies difficult to interpret and
compare.
Depression is associated with less than optimal diabetes
self-management, lower levels of physical activity and poorer
control of diabetes, with a subsequent greater risk of poor
microvascular and macrovascular outcomes, higher mortal-
ity rates and substantially increased healthcare costs [7,8].
There is evidence that depression can be treated success-
fully with both psychological and pharmacological interven-
tions, but under-recognition of mental disorders is a
significant barrier to successful care [9–11]. Translating the
findings of previous studies into clinical practice remains a
challenge, particularly when recommendations developed in
one country are offered for use in different cultural and
contextual settings, where resources are often lacking
[11–13]. In addition, depression may overlap with the
emotional distress associated with having and managing
diabetes, leading to additional challenges to the provision of
appropriate care [14].
This study was conducted under the auspices of the
Dialogue on Diabetes and Depression (http://diabetesa
nddepression.org/), an international multidisciplinary group
of academics and practitioners whose aim is to promote the
importance of comorbid diabetes and depression, provide
education and undertake research in this field. The main
objective of the present study was to investigate the preva-
lence and treatment of depression in people with Type 2
diabetes in 14 countries. We have conducted a collaborative
study using the same protocol in these countries which differ
in level of socio-economic development, cultural setting and
level of service development, using standardized ways of
identifying depressive disorders. The present study is the first
of its kind to use both a clinical interview as well as a
screening instrument to detect clinical depression and
depressive symptoms, and to also record the diagnoses of
diabetes complications contained in medical records kept by
leading centres of care for people with diabetes.
Methods
A full description of the protocol used in the present study is
provided in our earlier paper [15]. In brief, between
September 2013 and May 2015 a sample of consecutive
outpatient clinic attendees with Type 2 diabetes at each of
the study sites was invited to participate in the study, with
the aim of including 200 people with Type 2 diabetes in each
country. Site investigators, recruited from leading centres of
excellence in each country, included at least one psychiatrist
and endocrinologist for each country. The treating physician/
diabetologist in the diabetes clinic invited individuals to
participate in the study. Diabetes clinics were based in either
secondary or tertiary care centres, depending on the facilities
available in each country. Written informed consent was
obtained from all participants.
Inclusion/exclusion criteria
Eligible study participants were adults (aged 18–65 years)
with Type 2 diabetes [15] diagnosed at least 12 months
What’s new?
• Our study, unlike previous ones, used a standardized
clinical interview to measure depressive disorders in
people with diabetes in 14 countries.
• Although depressive disorders were frequently present
in people with Type 2 diabetes, in most cases, these
were neither diagnosed nor treated.
• We have identified particular factors associated with
depressive disorders which could be considered when
developing training for healthcare professionals in ways
to identify and manage comorbid depression and
diabetes.
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before the point of contact attending their diabetes outpatient
facilities. Individuals were excluded if they had been diag-
nosed with Type 2 diabetes for <12 months as it is usual to
experience a period of adjustment when first diagnosed.
Other exclusion criteria were: diagnosis of Type 1 diabetes;
inability to complete the survey tools because of communi-
cation or cognitive difficulties; and any life-threatening or
serious conditions (e.g. cancer, stroke in the last 6 months).
Those currently admitted or planning an admission for
inpatient care to a hospital (unless admitted for diabetes
self-management) were excluded because this groupmay have
been receiving more intensive or different treatment for their
diabetes and so were less comparable with those not
admitted. Women who were pregnant or had given birth in
the last 6 months were also excluded, as were those who had
received a clinical diagnosis of dependency on alcohol or
other substance (not tobacco) or a diagnosis of schizophrenia.
Prior to interview the site investigators completed an
information form for each eligible individual. This form
included information from medical records, such as age,
duration of diabetes, family history of diabetes and presence/
history of diabetes complications. The latter included
cardiovascular disease, retinopathy, peripheral neuropathy,
peripheral vascular disease and renal disease and associated
disorders. Most recent measurements of blood pressure,
HbA1c, height and weight were also recorded; however,
because the timing of HbA1c measurements varied in terms of
proximity to the clinical interviews they were not used in the
data analysis. A diagnosis of current major depressive
disorder (MDD) was made at interview so that the proximity
of clinical records did not differ. Any documentation of
prescribed medications for depression or other mental health
problem in each individual’s medical records was noted, as
was any documented diagnosis or treatment of any psychi-
atric condition. Participants were asked if they lived in what
they considered to be a rural or an urban area, and reported
their highest level of education (defined as no formal, some/
completed primary, some/completed secondary school, or
higher education, which was defined as any college, post-
graduate or professional training). Marital status was defined
as married/cohabiting vs being single/widowed/divorced
which, for our analyses, was dichotomized into living alone
vs not living alone. Participants were also asked if they
considered that they had a regular income.
Each participant was asked to complete the Patient Health
Questionnaire (PHQ-9) and the Problem Areas in Diabetes
(PAID) scale. The PHQ-9 consists of nine items on a four-
point Likert-type scale [17]. It has good sensitivity and
specificity with regard to identifying cases of depression as
well as being sensitive to change over time, and has been used
in a number of different countries [17]. Moderate/severe
depressive symptomatology was defined as PHQ-9 scores >
9, as this was a research study rather than clinical practice,
in which a significant level of symptoms would usually be
considered to be PHQ-9 scores >15 [11]. The PAID scale is a
20-item questionnaire which measures the extent of dia-
betes-related emotional distress [18]. Items include ‘feeling
overwhelmed with your diabetes’ and ‘feelings of guilt or
anxiety when you get off track with your diabetes manage-
ment’. Moderate/severe levels of diabetes-related distress are
defined as scores (standardized to 100) >40 [18]. All
questionnaires were completed using standard self-complete
methods in the appropriate language, or assisted one-to-one
collection, with the questions read out by the researcher and
answered by the participant. Where no existing translation/
cultural adaption of the questionnaire was available it was
adapted using standard forward/back translation proce-
dures. In addition, each country’s investigators ensured the
questionnaires were culturally applicable through their
development over several iterative stages, involving discus-
sion and testing by a range of healthcare professionals and
people with Type 2 diabetes and focusing on the meaning of
terms as well as language.
A psychiatric interview was subsequently conducted by a
trained interviewer using the Mini International Neuropsy-
chiatric Interview (V5 or V6 depending on current psychi-
atric practice at the study site) [19]. The Mini International
Neuropsychiatric Interview has been widely used in a range
of different populations, including those with serious illness,
and in community surveys, and is a reliable diagnostic tool
according to Diagnostic and Statistical Manual of Mental
Disorders 5th edition (DSM-V) criteria [20] as long as
appropriate training is given. Individuals diagnosed with
depression (or other psychiatric disorders such as anxiety
disorders) were advised to consult their physician for further
assessment and treatment. If any individual indicated suici-
dality (question 9 on the PHQ-9) the psychiatrist conducting
the clinical interview initiated immediate appropriate care.
Where required, all those collecting the data were trained in
the use of the Mini International Neuropsychiatric Interview
by the relevant senior staff. Depression was defined at
interview as a current (within 2 weeks) diagnosis of MDD in
accordance with the criteria given in the International
Classification of Diseases 10 classification (and the corre-
sponding criteria of MDDs in the DSM-IV). Previous MDD,
lifetime (i.e. either current or previous MDD) and recurrent
MDD (i.e. with both current and previous MDD) were also
diagnosed at interview.
Ethical approval
Prior to commencing the study, ethical approval was
obtained in all study settings. Ethical approval also was
obtained from the Open University, UK, where the data were
stored for analysis.
Statistical analysis
SPSS [23] was used to analyse the data. Descriptive statistics
are reported, along with univariate (t-test, chi-squared test,
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Wilcoxon rank-sum test) analyses to examine the differences
between those with and without current MDD and those
with PHQ-9 scores above and below the threshold for
moderate/severe depressive symptomatology (threshold >9).
Missing data are indicated in the relevant tables for each
country. Fewer than 3% of our data were missing, and could
be regarded as missing completely at random for the
predictors. After performing Little’s missing-completely-at-
random test (chi-squared =30.26, P=0.991), we imputed
these missing data using hotdeck imputations [22] where a
random draw from a subset of comparable cases by country,
sex and education is imputed using the Bayesian bootstrap
method of Rubin and Schenker [23].
We then used multivariable generalized estimating equa-
tions [24] with a binary logistic regression to examine risk
factors for current MDD and PHQ-9 score >9 while
controlling for country-specific effects. Only the variables
that were significantly associated with MDD or moderate/
severe depressive symptomatology in the bivariate analysis
were included. Estimations were calculated using an
exchangeable working correlation structure. Predictor vari-
ables included demographic, anthropometric and diabetes-
specific variables, and psychosocial variables. Having two
models enabled us to compare the results for current MDD
with moderate/severe depressive symptomatology.
Results
Response rates
A total of 2783 individuals with Type 2 diabetes agreed to
participate in the study, a response rate of 92.3%. Response
rates differed according to country of study, ranging from
64.7% (Ukraine) to 100% in Uganda, Mexico and India.
Women were more likely to participate than men (93.7 vs
90.8%; P=0.003). The main reason for not participating was
being too busy to remain in the clinic to undergo the
examination. Participants were younger than non-partici-
pants (53.54  9.20 vs 55.26  10.80 years; P=0.010), but
diabetes duration was not significantly different between
those who agreed to participate and those who did not.
Those without a regular income were more likely to
participate than those who did (97.1 vs 92.6%; P<0.0001).
Table 1 provides the overall details of the participants;
country-specific information is provided in Tables S1 and S2.
Overall, a slightly lower proportion of men participated and
the majority of participants (72.7%) were married or
cohabiting. Only 7.4% had no formal education, 30.8%
had a higher education level, and 16.8% had no regular
income. In total, 50.8% of participants had one or more
complications, with retinopathy and neuropathy being the
most commonly diagnosed.
Overall, 10.6% of participants were diagnosed with
current MDD at interview (Table 1) and 16.6% had lifetime
MDD. Rates of current MDD differed widely among
countries, ranging from 1% (Uganda) to 29.9% (Bangladesh;
Table S2). Rates of lifetime MDD ranged from 1% (Uganda)
to 32.5% (Russia). Similarly, the proportion of participants
with a previous MDD was 10.5%, ranging from 0.5%
(Uganda) to 21.0% (Russia). Recurrent MDD rates were
much lower than this (4.6%; ranging from 0% in Uganda/
Ukraine to 17.0% in Bangladesh). Nearly half (43.6%) of
those with current MDD had a previous diagnosis of
depression.
The proportion of individuals reporting moderate/severe
depressive symptomatology (PHQ-9 scores >9) was higher
than the current MDD diagnosis rate (17.0%; ranging from
1% in Uganda to 32.5% in Bangladesh). The majority
(72.5%) of those with current MDD had moderate/severe
depressive symptomatology. Overall, 12.8% of participants
reported moderate/severe (scores >40) levels of diabetes-
related distress (PAID scores).
Bivariate associations
Those with current MDD were significantly more likely to be
diagnosed with panic disorder than those without current
Table 1 Profile of INTERPRET-DD participants (total sample)
Demographic profile
Men, n (%) 1261 (45.3)
Age, years 54.1 (9.1) 5
Married/co-habiting, n (%) 2019 (72.5)5
Urban location, n (%) 2372 (85.4)4
Higher education, n (%) 856 (30.8)1
No regular income, n (%) 468 (16.8)2
Current smoker, n (%) 374 (13.5)
Exercise (at least weekly), n (%) 1643 (59.0)18
Diabetes specific and anthropometric profile
Diabetes duration, years 8.8 (6.7) 78
BMI, kg/m2 28.86 (6.07) 37
Insulin use, n (%) 1164 (41.8) 9
Number of complications, n (%)
0 1369 (49.2)
1 735 (26.4)
2 353 (12.7)
3 178 (6.4)
4 90 (3.2)
≥5 58 (2.1)
Psychological profile
Current MDD 294 (10.6)
Previous MDD 297 10.7) 6
Recurrent MDD* 128 (4.6) 6
Lifetime MDD* 463 (16.6) 5
Moderate/severe depressive
symptomatology (PHQ-9 >9)
466 (17.0) 48
PAID (diabetes distress) score >40 352 (12.8) 52
MDD, major depressive disorder; PAID, Problem Areas in
Diabetes.
Values are mean (sd) except where indicated.
*Lifetime MDD: current or previous MDD; recurrent MDD:
both current and previous MDD.
Numbers in italics are the number of participants with missing
data for that variable.
Country-specific rates are shown in Table S2.
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MDD (14.7 vs 2.7; chi-squared (1) = 100.11, P<0.0001).
Similarly those with current MDD were significantly more
likely to have post-traumatic stress disorder (7.2 vs
3.1%; chi-squared (1) = 12.69, P<0.0001) or generalized
anxiety disorder (22.9 vs 4.6%; chi-squared (1) = 144.8,
P<0.0001). There were also significant differences in the
proportion of people with and without current MDD who
also received a diagnosis of social anxiety disorder (8.9 vs
1.9%, respectively; chi-squared (1) = 51.07, P<0.0001) or
psychotic disorder (1.0 vs 0.2%, respectively; chi-squared (1)
= 5.0, P<0.05).
Those with moderate/severe depressive symptomatology
were significantly more likely to be diagnosed with panic
disorder than those with low scores (12.5 vs 2.2%; chi-
squared (1) = 108.69, P<0.0001). Similarly those with
moderate/severe depressive symptomatology were signifi-
cantly more likely to have post-traumatic stress disorder
(8.0 vs 2.4%; chi-squared (1) = 37.12, P<0.0001) or
generalised anxiety disorder than those without (17.0 vs
4.4%; chi-squared (1) = 100.71, P<0.0001). There were also
significant differences in the proportion of people with or
without moderate/severe depressive symptomatology who
also received a diagnosis of social anxiety disorder (5.4 vs
2.1%; chi-squared (1) = 16.36, P<0.0001) or psychotic
disorder (1.1 vs 0.2%; chi-squared (1) = 9.51, P<0.01).
Overall, those with current MDD were significantly more
likely to be women (women, 73.1% vs men, 26.9%; chi-
squared (1) = 45.07, P<0.0001). Age and smoking prefer-
ences did not significantly differ between those with or
without current MDD but longer duration of diabetes (z = –
4.6, Prob > |z| < 0.0001), less exercise (z = 4.11, Prob > |z| <
0.0001), and lower education level (z = 2.6, Prob > |z| < 0.05)
did. Participants who were on insulin were twice as likely to
have a current MDD diagnosis than those not taking insulin
(14.5 vs 7.8%; chi-squared (1) =32.7, P<0.0001), and had a
greater BMI than those without current MDD (29.7 6.6 vs
28.8  6.0 kg/m2; P<0.05).
Those with current MDD were significantly less likely to
be married or cohabiting than those without current MDD
(67.4 vs 73.3%; chi-squared (1) = 4.69, P<0.05), were more
likely to report a lack of regular income (22.5 vs 16.5%; chi-
squared (1) = 6.5, P<0.01) and were significantly more likely
to be living in an urban rather than rural location (90.8 vs
84.4%; chi-squared (1) = 8.5, P<0.01).
Those with current MDD were significantly more likely to
have a diagnosis of past MDD than those without current
MDD (43.7 vs 6.8%; chi-squared (1) = 372.9, P<0.001).
Participants with current MDD were more likely to report
moderate/severe levels of diabetes-related distress than those
without current MDD (34.0 vs 10.7%; chi-squared (1)
=125.5, P<0.001). Overall, those with current MDD were
significantly more likely to have nephropathy (16.0 vs 9.8%;
chi-squared (1) =10.23, P<0.01), neuropathy (47.2 vs
24.3%; chi-squared (1) = 69.4; P<0.0001) and stroke (9.6
vs 6.1%; chi-squared (1) = 5.15, P=0.05). The proportion of
those individuals with current MDD significantly increased
with the number of complications they had, from 6.5% of
those without any complications to 15.5% of those with five
or more complications (z = –7.3, Prob > |z| < 0.001).
Those with moderate/severe depressive symptomatology
were more likely to be women (69.7%; chi-squared (1) =
51.1; P<0.0001). Age and smoking preferences did not
significantly differ between those with or without moderate/
severe depressive symptomatology, but longer duration of
diabetes (z=-4.7 Prob>|z|<0.0001), less exercise (z = 5.4, Prob
> |z| < 0.0001), and less education (z = 4.9, Prob > |z| <
0.0001) did significantly differ between those with and
without moderate/severe depressive symptomatology. Those
taking insulin were significantly more likely to have moder-
ate/severe depressive symptomatology than those not taking
insulin (21.6 vs 13.7%, respectively; chi-squared (1) = 29.4,
P<0.0001). In addition, BMI was significantly greater in
those with moderate/severe depressive symptomatology
(29.6  6.5 vs 28.7  6.0, P<0.01). Those with moderate/
severe depressive symptomatology were significantly less
likely to be married or cohabiting than those without current
MDD (68.0 vs 73.9%; chi-squared (1) = 6.8, P<0.01) and
were more likely to report having no regular income (28.5 vs
14.9%; chi-squared (1) = 50.9, P<0.0001). There was no
significant association between the likelihood of living in an
urban vs a rural area according to PHQ-9 scores. Those with
moderate/severe depressive symptomatology were much
more likely to have a diagnosis of previous MDD than those
with lower scores (46.1 vs 13.6%; chi-squared (1) = 194.0,
P<0.0001). Participants with moderate/severe depressive
symptomatology were more likely to report moderate/severe
levels of diabetes-related distress than those without (35.8 vs
8.4%; chi-squared (1) = 255.9, P<0.0001).
Overall, those with moderate/severe depressive symptoma-
tology were significantly more likely to have nephropathy
(13.5 vs 9.9%; chi-squared (1) = 5.2, P<0.05) and neuropa-
thy (43.5 vs 23.1%; chi-squared (1) = 80.9, P<0.0001) than
those without. The proportion of those with moderate/severe
depressive symptomatology significantly increased with the
number of complications they had, from 12.0% of those
without any complications to 23.6% of those with five or
more complications Z=–7.5 (Prob> |z| <0.0001).
Multivariable results
As shown in Table 2, significant predictors of current MDD
(controlling for country) were female gender, lower educa-
tion level, insulin treatment, higher PAID scores, previous
MDD, and less exercise. For current MDD, women had a
statistically significant odds ratio of 1.96 vs men. Compared
with participants who did not regularly exercise, those who
exercised daily had a significantly lower risk of current MDD
(odds ratio 0.88). Compared with PAID scores ≤40, partic-
ipants with a score >40 had significantly higher odds of
current MDD (2.88), while people with previous MDD had
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a statistically significant odds ratio of 7.46 of occurrence of
current MDD compared with those without previous MDD.
Higher education level significantly decreased the odds of
MDD vs no education, whereas primary and secondary levels
did not.
Similar associations were found in a separate model
examining the variables associated with moderate/severe
depressive symptomatology, with the exceptions of insulin
treatment (only significant for the MDD model) and having
fewer diabetes complications, which significantly decreased
the odds of moderate/severe depressive symptomatology.
Lack of a regular income increased the odds of having
moderate/severe depressive symptomatology.
Between 0 and 37.5% of those with current MDD had
any documentation of medications and between 0 and 20%
had a diagnosis of a psychiatric disorder (including MDD)
in their medical records (Table 3). Similarly, between 0 and
66.7% (two-thirds of cases) and 0 and 28.6% of those with
recurrent MDD had either documentation of medications or
a diagnosis in their medical records. Rates were similar in
those with moderate/severe depressive symptomatology
(Table 3). Even in those countries where there was some
evidence of documented diagnoses/medications, very low
rates were observed; for example, in Italy three out of eight
people with current MDD had medications documented
and only one in eight had a diagnosis documented. There
was no significant difference in recording of medications
between those with current (and no previous or recurrent)
vs those with recurrent MDD (36.4 vs 63.6%; chi-squared
(1) = 1.3, P=0.25); however, those with recurrent MDD
were significantly more likely to have a diagnosis of
depression recorded in their medical records than those
with current MDD (75.0 vs 25%; chi-squared (1) = 5.6,
P<0.05).
Discussion
We observed substantial rates of mental health problems in
the present study, with 10.6% of participants receiving a
clinical diagnosis of current MDD and 17% reporting
moderate/severe depressive symptomatology as measured
by the PHQ-9. Furthermore, 16.6% had lifetime but only
4.6% had recurrent depression. Worryingly, the proportion
of those with current MDD who had a diagnosis or
treatment for their depression noted in their medical records
was for the most part extremely low, and non-existent in
many countries, suggesting a lack of joined-up care for those
with comorbid diabetes and depression. Fewer than half
(45.3%) of those with moderate/severe depressive symp-
tomatology were diagnosed with current MDD at interview,
suggesting that the former questionnaire may well identify
individuals as being depressed who do not meet the criteria
for diagnosis, or the perceptions of people with diabetes as to
their difficulties in dealing with their diabetes.
The present INTERPRET-DD study was a collaborative
study of the prevalence of depressive states that used the
same protocol and was carried out at the same time in 14
different countries. It included almost 3000 people with a
clinical diagnosis of Type 2 diabetes [15]. Overall our
response rate was extremely high, most likely because of the
place of recruitment (diabetes clinic) and the person doing
the recruiting (the treating physician). However, the study
has a number of limitations. Although the total number of
study participants reached almost 3000, numbers in some
Table 2 Demographic, anthropometric, diabetes-specific, lifestyle and psychosocial predictors of current major depressive disorder and moderate/
severe depressive symptomatology, determined by generalised estimating equation logistic regression
Variables
Current MDD
Moderate/severe depressive
symptomatology (PHQ-9 score >9)
Odds ratio 95% CI P Odds ratio 95% CI P
Sex female vs male* 1.96 1.54; 2.51 <0.0001 1.70 1.43; 2.02 <0.0001
Marital status not married vs married* 0.97 0.76; 1.24 0.83 1.00 0.88; 1.14 0.99
Education level 0.81 0.68; 0.96 0.01 0.73 0.64; 0.83 <0.0001
Regular family income no vs yes* 1.28 0.94; 1.74 0.12 1.99 1.43; 2.77 <0.0001
Location of residence rural vs urban* 0.69 0.45; 1.05 0.08
BMI 1.00 0.98; 1.02 0.96 1.01 0.98; 1.03 0.70
Duration of diabetes 1.03 0.98; 1.03 0.82 1.01 0.997; 1.03 0.11
Insulin treatment no vs yes* 0.77 0.61; 0.97 0.03 0.88 0.67; 1.15 0.36
Number of diabetes complications 1.18 0.98; 1.43 0.08 1.17 1.00; 1.35 0.04
Exercise level 0.88 0.78; 0.98 0.02 0.88 0.82; 0.94 <0.0001
PAID score high ≥40 vs low<40* 2.88 1.99; 4.17 <0.0001 5.59 3.54; 8.85 <0.0001
Previous MDD yes vs no* 7.46 4.26; 12.99 <0.0001 3.97 2.68; 5.88 <0.0001
MDD, major depressive disorder; PAID, Problem Areas in Diabetes; PHQ-9, Patient Health Questionnaire.
*Denotes reference category;
Comparison of the two models to test if the odds ratio for one model falls outside the CI for the other model where the variables are
significant in at least one model: the model is not significantly different except for previous MDD, PAID scores (significant in both the models
but had odds ratio higher in one model than the CI) and family income (significantly associated only with moderate/severe depressive
symptomatology with higher odds ratio for the moderate/severe depressive symptomatology model than the CIs of the first model).
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countries were lower than in others and there were too few
cases of MDD in many of the countries, which made it
difficult to perform site-specific analyses, for example,
comparing the socio-economic differences among countries.
We cannot say for certain, therefore, that the different rates
were not attributable to between-country characteristics. The
data collected from participants’ medical records were
extensive, but, although participants were recruited at their
usual clinic appointment, some information may have been
missed when records were kept in more than one place. The
study was undertaken in specialist clinics where the case mix
may be different from the wider diabetes population,
therefore, there may be an overestimate of the risk of
depression. Some countries may have less extensive medical
records than others or may be less likely to document a
diagnosis of a condition (either physical or mental) that in
many cultures is often perceived as stigmatized and so is less
likely to be acknowledged. Identifying symptoms of depres-
sion or distress using tools that were originally developed in
Europe/North America may also be problematic despite their
extensive development for use in other cultures [25]; for
example, symptoms of distress may seem to be associated
with the personal experience of physical illness and so not
reported or identified as depression. Our results show that
there is a significant difference between both diabetes distress
(PAID score) and PHQ-9 scores according to the country of
the study (Manova P<0.0001; Table S2, footnote). This may
be attributable to different cultural experiences of symptoms;
for example, in Uganda low rates may be related to the
moderating effect of particular cultural practices where,
when a person falls ill, the whole family and community are
involved in care, in contrast to other countries where the
focus is on the individual.
There may be different interpretations with regard to the
variables ‘regular income’ and ‘rural area’, which may have
limited our analysis when we included these variables.
Nevertheless, we would argue that it is the participants’
understanding of their life situation that is important, as is
their reporting of whether they feel depressed or anxious
about their diabetes.
In spite of the above-mentioned caveats, the major
advantages of the present study are the large sample in 14
countries, which involved a clinical diagnosis of depression
by specially trained interviewers using the same methods
rather than solely relying on checklists to record depressive
symptoms, and the use of standard methods for translating
any questionnaires that had not been translated and vali-
dated before. The study took place in each participant’s usual
place of care, where opportunities for identifying symptoms
of depression and/or distress may exist.
In the present study, we confirmed previous findings from
other countries in Europe that depressive disorders are
common in people with diabetes. We identified differences
in the prevalence of depressive symptoms, as well as the
clinical diagnosis of depression among the countries. This
may reflect differences in the acceptance/stigma (or indeed
denial) of acknowledging symptoms of psychological and
emotional distress in different cultural groups. The results of
the present study showing significant multivariable associa-
tions of current MDD diagnosis with demographic and
Table 3 Number of recorded medications for depression or diagnosis of depression in those with diagnosed MDD (current and recurrent) and
moderate/severe depressive symptomatology at interview
Country
Current MDD (diagnosed at interview) Recurrent MDD (diagnosed at interview)
Moderate/severe depressive
symptomatology (PHQ-9
score >9)
Number with
medications
documented
Number with a
documented diagnosis
Number with
medications documented
Number with a
documented
diagnosis
Number with
medications
documented
Number with a
documented
diagnosis
Argentina 0/16 0/16 0/10 2/10 0/18 2/18
Bangladesh 0/58 0/58 0/33 0/33 0/63 0/63
China 0/42 3/42 0/7 2/7 0/56 2/56
Germany 0/5 1/5 0/4 1/4 1/19 2/19
India 0/4 0/4 0/1 0/1 0/31 5/31
Italy 3/8 1/8 2/3 1/3 7/26 7/26
Kenya 0/5 0/5 0/0 0/0 2/22 0/22
Mexico 2/37 3/37 2/18 1/18 2/61 4/61
Pakistan 1/24 0/24 0/5 0/5 0/41 1/41
Poland 0/32 4/32 0/22 4/22 0/30 3/30
Russia 1/34 0/34 0/11 0/11 0/47 0/47
Serbia 4/19 2/19 3/13 1/13 4/27 3/27
Uganda 0/2 0/2 0/1 0/1 0/2 0/2
Ukraine 0/8 0/8 0/0 0/0 0/23 0/23
TOTAL 11/294 14/294 7/128 12/128 16/466 29/466
MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire.
Medications documented: any documentation of prescribing medications for depression or other mental health problem in individual
participant’s medical records.
Documented diagnosis: any psychiatric condition reported as diagnosed or treated in individual participant’s medical records.
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psychosocial variables are generally consistent with those of
other cross-sectional studies carried out in the UK and USA
using self-reported symptoms of depression. Although a
somewhat similar pattern emerged when using a moderate/
severe PHQ-9 score as the dependent variable, stronger
associations were observed with income and complications,
reflecting the importance of diabetes-related factors and
wider life issues [26]. Although measures differ across stud-
ies, depression, whether assessed by self-reported symptoms
or by diagnostic interviews, has been found to be strongly
associated with gender, lower education level [26,27],
physical inactivity [28] and previous depression [27]. Con-
sistent with other studies, we found significant links between
MDD and diabetes complications, although the latter was a
stronger predictor in the moderate/severe depressive symp-
tomatology model [29,30]. Mean age and BMI in the present
study were comparable with data from other multinational
studies such as the DAWN2 study [31]; however, the
percentage of people treated with insulin was higher in the
present study than in the DAWN2 study, which may be
explained by the fact that participants in the latter study
were stratified by type of treatment, while the present study
only included participants from secondary care, who are
more likely to be treated with insulin.
Interestingly, we found that diabetes-related distress was a
significant independent predictor of MDD and also moder-
ate/severe depressive symptomatology. Recent research has
shown that, although depressive symptoms and distress
overlap to some extent, they are not interchangeable
[16,32]. While it is sometimes difficult to distinguish between
them, the present study indicates that the two measures
assess distinct constructs, with many people reporting high
levels of depressive symptoms who did not report significant
levels of diabetes-related emotional distress.
There are now a number of national and international
guidelines for supporting people with diabetes and mental
health difficulties, and research into the psycho-emotional
consequences of diabetes has been increasing in recent years
[4,5,9,31–34]; however, although it has been acknowledged
that mental disorders massively contribute to the numbers of
years lost through disability [35], there remain barriers to
access of services that would improve mental health, partic-
ularly in countries where resources are often unavailable.
The situation is even worse when it comes to the comorbidity
of mental and physical disorders, which is undoubtedly one
of the major problems with regard to healthcare in the 21st
century [35]. Based on our observations in the present study,
the feasibility of using different therapies for the treatment of
comorbid diabetes and depression rests on a number of
factors. In particular the range of available treatments within
each local context [15], the awareness of those caring for
people with these two conditions, the acceptance of the need
and preferences for treatment and the demonstrability of
successful outcomes are all important factors that influence
the applicability of different therapies in different settings.
The countries involved in the INTERPRET-DD study have
found that multi-disciplinary care and improved liaison
between different specialties are key to improving care, but
many countries still do not have national guidelines which
can be implemented locally.
The present study draws attention to the magnitude and
significance of comorbid depressive disorders and diabetes,
both of which are of growing prevalence and public health
significance. The burden of complications in association with
MDD has important implications for both the individual
with diabetes and also health services provision. Our finding
that a previous MDD was predictive of current MDD
underscores the need for better understanding of and
monitoring and treatment for mental illness; however,
mental health care is not likely to receive any attention until
what are seen as more pressing needs for physical care are
met. Although we determined the broad range of treatments
available in each country before commencing data collection,
we did not recorded any non-pharmacological treatments at
baseline. Our follow-up study will rectify this, however, as
the treatment journey for every person diagnosed at baseline
will be recorded. We have found an almost non-existent
recording of any symptoms of/medications prescribed for
depression in the medical records of those to whom we gave
a clinical diagnosis of MDD. This may be for a number of
reasons, which require further investigation. Our research
supports previous studies in which low recognition rates have
also been observed [36,37]. Awareness of the importance of
mental health problems is a first step towards improving
care, but improved service provision is of major importance.
Although better screening could be recommended, serious
consideration must be given to the ethical quandary of
identifying those who require psychological support where
there is no treatment available to offer. Healthcare profes-
sionals may understandably be reluctant to make a diagnosis
of depression (or indeed any other psychological problem) if
care is not available.
Longitudinal studies are vital if we are to understand the
impact of depression and other mental health problems on
diabetes, its management and the development of other
comorbidities.
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